NEW YORK (GenomeWeb) – Following the planned launch of a series of liquid biopsy cancer tests over the next six months, Transgenomic is aiming to broadly license the multiplexed PCR-based technology that powers the products to instrument and reagent firms, according to President and CEO Paul Kinnon.

Once it has done so, Kinnon told GenomeWeb this week, the firm plans to decide whether there are any applications or specific disease areas in which it wants to maintain exclusivity with the technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.